Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

March 23, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Filanesib, pomalidomide and dexamethasone

Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.

Trial Locations (10)

28041

Hospital Doce de Octubre, Madrid

30008

Hospital Morales Messeguer, Murcia

31008

Clínica Universitaria de Navarra, Pamplona

37007

Hospital Clinico Universitario Salamanca, Salamanca

40002

Hospital General de Segovia, Segovia

41013

Hospital Virgen del Rocío, Seville

46017

Hospital Universitario Dr Peset, Valencia

50009

Hospital Lozano Blesa, Zaragoza

08916

Instoitut Català d'Oncologia, Badalona

08036

Hospital Clinico Universitario, Barcelona

Sponsors
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

PETHEMA Foundation

OTHER